Source comparison
Comparison: BPC-157 vs Standard Tennis Elbow Treatments
BPC-157 Peptide Upregulates VEGF and FAK-paxillin pathway to enhance fibroblast activity and angiogenesis 2–4 weeks with consistent dosing Direct: stimulates organized collagen type I deposition Addresses core pathology (degeneration) rather than symptoms. Not
This comparison does not assign a generated winner or score.
- BPC-157 Peptide
- Upregulates VEGF and FAK-paxillin pathway to enhance fibroblast activity and angiogenesis
- 2–4 weeks with consistent dosing
- Direct: stimulates organized collagen type I deposition
- Addresses core pathology (degeneration) rather than symptoms. Not FDA-approved. Requires pharmaceutical-grade sourcing.
- NSAIDs (Ibuprofen)
- Inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis
- 1–7 days for acute pain
- None: may impair healing by suppressing early inflammatory signals needed for tissue repair
- Symptom management only. Does not address tendon structure. May delay healing if used long-term.
- Corticosteroid Injection
- Suppresses local immune response and reduces swelling
- 24–72 hours (short-term relief)
- Negative: inhibits collagen synthesis and VEGF expression
- High relapse rates (>50% at 6 months). Risk of tendon weakening with repeat injections.
- Eccentric Exercise Therapy
- Mechanotransduction stimulates tenocyte differentiation and collagen alignment
- 6–12 weeks with structured protocol
- Indirect: controlled loading triggers adaptive collagen remodeling
- Gold standard for tendinosis. No direct biological enhancement. Relies on body's natural healing capacity.
- Platelet-Rich Plasma (PRP)
- Delivers concentrated growth factors (PDGF, TGF-β) to injured tissue
- 4–8 weeks for measurable improvement
- Moderate: growth factors stimulate collagen synthesis but effect depends on platelet concentration and preparation
- Variable outcomes. Requires procedural skill for correct injection site and platelet activation.